Finkelstein Thompson LLP Announces Investigation of RehabCare Group, Inc.

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of RehabCare Group, Inc. (“RehabCare” or the “Company”) (NYSE: RHB) concerning the sale of the Company to Kindred Healthcare, Inc. (“Kindred”) (NYSE: KND) for $26.00 per share in cash and 0.471 of a share of Kindred common stock. Based on the average value of Kindred common stock in the preceding ten trading days prior to signing of the definitive merger agreement, each RehabCare shareholder will receive consideration valued at approximately $35 per share. The total consideration value is approximately $1.3 billion.

The investigation is focused on the potential unfairness of the consideration to RehabCare shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among RehabCare Board members. If you are interested in discussing your rights as a RehabCare shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Rehabcare (NYSE:RHB)
Historical Stock Chart
From Jun 2024 to Jul 2024